Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 10, 2007

MorphoSys Expands Agreement with GeneFrontier to Tap More Therapeutic Targets

  • MorphoSys and GeneFrontier signed an agreement focusing on therapeutic target sourcing. This is an expansion of an existing marketing alliance with GeneFrontier.

    Research institutes in Japan will be offered access to MorphoSys’ HuCAL-based research antibodies against novel disease-related target molecules, while MorphoSys retains commercialization rights. Also, antibodies for selected projects will be generated by GeneFrontier using HuCAL antibody technology.

    MorphoSys will have access to all research results and data around the selected research programs and the option to secure worldwide rights on such antibody programs.

    In September 2004, MorphoSys and GeneFrontier signed a strategic marketing agreement to access the Japanese life science market. In 2006, both parties expanded the agreement to cover the generation of HuCAL-derived fully human antibodies for proteome research and target validation.

    “GeneFrontier will now act as a hub and allow us to benefit from the research results of leading research institutes,” explains Simon Moroney, D. Phil, CEO of MorphoSys. “We are convinced that building a network of relationships with leading, medically-focused academic institutes is a productive way of accessing the therapeutic targets of tomorrow. Access to these innovative new drug targets will further strengthen MorphoSys' proprietary drug development capabilities.”

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »